Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ImmuCell Corp

ICCC ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: N/A

Last Close

$10.05

▼ -7.80%

Market Cap $91.28M · Vol 33.87K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$91.28M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

27.12

Momentum

Beta

0.53

vs Market

52W High

$12.00

16.25% below

52W Low

$4.53

121.85% above

Volume

33.87K

Avg 8.54K

P/B

2.06

Price-to-book

ROE

N/A

Return on equity

Free Float

67.78%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, ImmuCell Corp (ICCC) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ICCC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.64%

-14.25%

+21.82%

+52.27%

YTD

+63.41%

+49.55%

+103.03%

+11.54%

Financials & Valuation

TTM · Annual

Total Revenue	$27.64M
Net Income	$-1,040,030.00
Revenue Growth (YoY)	+11.50%
Gross Margin	41.40%
Operating Margin	5.97%
Net Profit Margin	-3.76%
ROE	N/A
ROA · ROIC	-2.35% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	2.01
P/B	2.06
P/FCF	45.32
EPS Growth	N/A
Outstanding Shares	9.08M

Technical Indicators

50-Day SMA	$10.50
200-Day SMA	$7.72
RSI (14)	27.12
Beta	0.53
52-Week High	$12.00
52-Week Low	$4.53

Volume Today	33.87K
Avg Daily Volume (30D)	8.54K
Relative Volume	3.97x
Volatility (10D)	42.40
Volatility (30D)	51.96
Free Float	67.78%

Analyst Consensus

N/A

Current Price $10.05

Mean Target N/A

52W Low$4.53 52W High$12.00

Current

Target

$4.53 $12.00

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S5S3P1

ISINUS4525253062

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).